Phase 2 Colorectal Cancer Trial, Recruiting NCT07095439 Sponsor: Ain Shams University Condition: Colorectal Cancer
Back to Colorectal Cancer

Phase 2 Colorectal Cancer Trial, Recruiting

NCT07095439
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 70 years old
  • You have been confirmed by a laboratory test to have a specific type of rectal cancer (adenocarcinoma) located in the lower or middle part of the rectum, within 16 cm of the anal opening
  • Your cancer has been classified as Stage II or Stage III based on scans, meaning it has grown into surrounding tissue or spread to nearby lymph nodes, but not to distant parts of the body
  • You have had a CT scan of your chest, abdomen, and pelvis before treatment to assess the extent of your disease
  • You are generally able to carry out day-to-day activities, with little to no limitation from your illness (confirm with trial site)
  • Your blood test results meet certain minimum levels for white blood cells, platelets, haemoglobin, kidney function, and liver function (confirm with trial site for specific values)
  • You are able and willing to provide written consent to participate

Who may not be able to join:

  • You have previously had surgery to treat your rectal cancer, or you have an active inflammatory bowel condition affecting the rectum that causes abnormal connections between body parts (fistulising disease)
  • Surgery or other medical treatments are not considered safe options for you for any reason
  • You have previously received radiotherapy to the pelvic area
  • You have been diagnosed with another cancer within the last 5 years
  • You have existing health conditions that make chemotherapy or radiotherapy unsafe, such as severe nerve damage or serious heart disease

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Khaled M Abdel Karim, MD, Faculty of medicine, Ain Shams University

Phone: +201061214926

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
1 September 2023
Est. completion
1 January 2026

Where this trial is recruiting

🇪🇬 Egypt

Primary endpoints

Pathological complete response

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov